Biofrontera Inc. 8-K

What Happened

• Biofrontera Inc. (BFRI) filed an 8‑K on February 26, 2026 reporting that the U.S. Patent Trial and Appeal Board (PTAB) issued a Final Written Decision on February 23, 2026 finding all challenged claims of Sun Pharmaceutical Industries’ U.S. Patent No. 11,697,028 unpatentable.
• Sun had earlier sued Biofrontera and affiliates in June 2024 in the U.S. District Court for the District of Massachusetts and at the U.S. International Trade Commission (ITC) alleging infringement of two Sun patents; Biofrontera filed separate PTAB petitions challenging both patents.

Key Details

• PTAB Final Written Decision date: February 23, 2026.
• Patent affected: U.S. Patent No. 11,697,028 — all challenged claims found unpatentable.
• Procedural options for Sun: may request rehearing, petition the USPTO Director for review, or appeal to the U.S. Court of Appeals for the Federal Circuit.
• The PTAB denied review of the Company’s petition on the other Sun patent; that petition remains separate.
• Impact on the District Court and ITC proceedings is not determinable at this time. Biofrontera issued a press release on February 26, 2026 and refers investors to Note 18 in its Form 10‑Q for the quarter ended September 30, 2025 for more background.

Why It Matters

• This PTAB ruling removes—or could reduce—the patent basis for at least one of Sun’s infringement claims, which may weaken Sun’s litigation and trade‑remedy positions if the decision stands.
• The decision is not final: Sun can seek rehearing or appeal, so legal risk and related financial exposure remain uncertain until lower‑court and ITC proceedings and any appeals are resolved.
• Investors should monitor further filings, appeals, and updates (including the company’s press releases and quarterly filings) for developments that could affect litigation outcomes and potential liabilities.